Action Novartis CDR - NVS

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

22,90

Prix Achat

22,58

Prix Vente

22,82

Volume échangé

1 270

22,84 Fourchette du Jour 22,90

0,00 Plage de 52 semaines 0,00

Clôture Veille

23,27

Ouverture

22,90

Dernière Transaction

22.9

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer PR...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

October 3, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

NVS - Frequently Asked Questions (FAQ)

What is the current Novartis CDR share price?

The current share price of Novartis CDR is $ 22,90

What is the 1 year trading range for Novartis CDR share price?

Novartis CDR has traded in the range of $ 0,00 to $ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
JPEGPioneer Media Holdings Inc	$ 0,39 (35,42%)	489,06k
CDMNCanadian Manganese Company Inc	$ 0,02 (33,33%)	988,5k
HOLDImmutable Holdings Inc	$ 0,14 (16,67%)	7,7k
DMETDenarius Metals Corp	$ 0,68 (15,25%)	5,5k
IBERIberAmerican Lithium Corp	$ 0,04 (14,29%)	10k
FHFilament Health Corp	$ 0,02 (-20,00%)	149,7k
INXDINX Digital Company Inc	$ 0,055 (-15,38%)	64k
BTQBTQ Technologies Corp	$ 3,04 (-6,75%)	208,67k
CBSTCannabist Company Holdings Inc	$ 0,07 (-6,67%)	414,3k
SUNNSolarBank Corporation	$ 5,40 (-5,59%)	3,05k
CDMNCanadian Manganese Company Inc	$ 0,02 (33,33%)	988,5k
DEFIValour Inc	$ 3,18 (-1,24%)	934,11k
ALGOLight AI Inc	0,68 (-5,56%)	833,67k
JPEGPioneer Media Holdings Inc	$ 0,39 (35,42%)	489,06k
CBSTCannabist Company Holdings Inc	$ 0,07 (-6,67%)	414,3k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novartis CDR (NVS)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

NVS Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Tesla Sales Drop; Intel to Exit Dow Jones After 25 Years; VKTX and ATSG Surge Over 20% Pre-Market

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HSBC Reports $8.5 Billion Profit; Boot Barn Announces New CEO and Projections; TMDX Drops 24%, VFC Surges 22%

NVS - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novartis CDR (NVS) Cours

Novartis CDR (NVS)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

NVS Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Tesla Sales Drop; Intel to Exit Dow Jones After 25 Years; VKTX and ATSG Surge Over 20% Pre-Market

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HSBC Reports $8.5 Billion Profit; Boot Barn Announces New CEO and Projections; TMDX Drops 24%, VFC Surges 22%

NVS - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR